GNFT: Genfit S.A. - Summary | Jitta

Genfit S.A.

NASDAQ:GNFT

Price
$3.67
Loss Chance
44.5%
3.21JITTA SCORE
33.94%Under Jitta Line
Jitta Ranking
26 / 1,197
501 / 5,063
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (41)
Recent Business Performance (73)
Financial Strength (55)
Return to Shareholders (24)
Competitive Advantage (53)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Recent IPOLess than 3 years
Revenue and EarningEarning loss detected in 2020
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
3.21
33.94%
1.31
114.85%
2.00
236.83%
Biotechnology
6.10
57.92%
5.54
31.25%
3.95
72.71%
COMPANY DESCRIPTION
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company’s products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.